Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 69

1.

Impact of ApoE Polymorphism and Physical Activity on Plasma Antioxidant Capability and Erythrocyte Membranes.

Piccarducci R, Daniele S, Fusi J, Chico L, Baldacci F, Siciliano G, Bonuccelli U, Franzoni F, Martini C.

Antioxidants (Basel). 2019 Nov 9;8(11). pii: E538. doi: 10.3390/antiox8110538.

2.

Plasma Levels of Oxidative Stress Markers, before and after BoNT/A Treatment, in Chronic Migraine.

Dini E, Mazzucchi S, De Luca C, Cafalli M, Chico L, Lo Gerfo A, Siciliano G, Bonuccelli U, Baldacci F, Gori S.

Toxins (Basel). 2019 Oct 19;11(10). pii: E608. doi: 10.3390/toxins11100608.

3.

Brain Aβ load association and sexual dimorphism of plasma BACE1 concentrations in cognitively normal individuals at risk for AD.

Vergallo A, Houot M, Cavedo E, Lemercier P, Vanmechelen E, De Vos A, Habert MO, Potier MC, Dubois B, Lista S, Hampel H; INSIGHT-preAD study group; Alzheimer Precision Medicine Initiative (APMI).

Alzheimers Dement. 2019 Oct;15(10):1274-1285. doi: 10.1016/j.jalz.2019.07.001.

4.

Biomarker-guided clustering of Alzheimer's disease clinical syndromes.

Toschi N, Lista S, Baldacci F, Cavedo E, Zetterberg H, Blennow K, Kilimann I, Teipel SJ, Melo Dos Santos A, Epelbaum S, Lamari F, Genthon R, Habert MO, Dubois B, Floris R, Garaci F, Vergallo A, Hampel H; INSIGHT-preAD study group; Alzheimer Precision Medicine Initiative (APMI).

Neurobiol Aging. 2019 Nov;83:42-53. doi: 10.1016/j.neurobiolaging.2019.08.032. Epub 2019 Sep 10.

5.

The neuroinflammatory biomarker YKL-40 for neurodegenerative diseases: advances in development.

Baldacci F, Lista S, Palermo G, Giorgi FS, Vergallo A, Hampel H.

Expert Rev Proteomics. 2019 Jul;16(7):593-600. doi: 10.1080/14789450.2019.1628643. Epub 2019 Jun 14.

PMID:
31195846
6.

A frontline defense against neurodegenerative diseases:the development of early disease detection methods.

Baldacci F, Lista S, Vergallo A, Palermo G, Giorgi FS, Hampel H.

Expert Rev Mol Diagn. 2019 Jul;19(7):559-563. doi: 10.1080/14737159.2019.1627202. Epub 2019 Jun 10. No abstract available.

PMID:
31159600
7.

Differential default mode network trajectories in asymptomatic individuals at risk for Alzheimer's disease.

Chiesa PA, Cavedo E, Vergallo A, Lista S, Potier MC, Habert MO, Dubois B, Thiebaut de Schotten M, Hampel H; INSIGHT-preAD study group; Alzheimer Precision Medicine Initiative (APMI).

Alzheimers Dement. 2019 Jul;15(7):940-950. doi: 10.1016/j.jalz.2019.03.006. Epub 2019 May 18.

8.

Plasma amyloid β 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease.

Vergallo A, Mégret L, Lista S, Cavedo E, Zetterberg H, Blennow K, Vanmechelen E, De Vos A, Habert MO, Potier MC, Dubois B, Neri C, Hampel H; INSIGHT-preAD study group; Alzheimer Precision Medicine Initiative (APMI).

Alzheimers Dement. 2019 Jun;15(6):764-775. doi: 10.1016/j.jalz.2019.03.009. Epub 2019 May 18.

PMID:
31113759
9.

Potential Diagnostic Value of Red Blood Cells α-Synuclein Heteroaggregates in Alzheimer's Disease.

Baldacci F, Daniele S, Piccarducci R, Giampietri L, Pietrobono D, Giorgi FS, Nicoletti V, Frosini D, Libertini P, Lo Gerfo A, Petrozzi L, Donadio E, Betti L, Trincavelli ML, Siciliano G, Ceravolo R, Tognoni G, Bonuccelli U, Martini C.

Mol Neurobiol. 2019 Sep;56(9):6451-6459. doi: 10.1007/s12035-019-1531-4. Epub 2019 Mar 2.

PMID:
30826968
10.

Sex differences in functional and molecular neuroimaging biomarkers of Alzheimer's disease in cognitively normal older adults with subjective memory complaints.

Cavedo E, Chiesa PA, Houot M, Ferretti MT, Grothe MJ, Teipel SJ, Lista S, Habert MO, Potier MC, Dubois B, Hampel H; INSIGHT-preAD Study Group; Alzheimer Precision Medicine Initiative (APMI).

Alzheimers Dement. 2018 Sep;14(9):1204-1215. doi: 10.1016/j.jalz.2018.05.014. Epub 2018 Jul 7. Review.

PMID:
30201102
11.

Effect of 5-Oxo-2-Pyrrolidinecarboxylic Acid (PCA) as a New Topically Applied Agent for Dry Eye Syndrome Treatment.

Tampucci S, Monti D, Burgalassi S, Terreni E, Zucchetti E, Baldacci F, Chetoni P.

Pharmaceutics. 2018 Aug 25;10(3). pii: E137. doi: 10.3390/pharmaceutics10030137.

12.

Association of cerebrospinal fluid α-synuclein with total and phospho-tau181 protein concentrations and brain amyloid load in cognitively normal subjective memory complainers stratified by Alzheimer's disease biomarkers.

Vergallo A, Bun RS, Toschi N, Baldacci F, Zetterberg H, Blennow K, Cavedo E, Lamari F, Habert MO, Dubois B, Floris R, Garaci F, Lista S, Hampel H; INSIGHT-preAD study group; Alzheimer Precision Medicine Initiative (APMI).

Alzheimers Dement. 2018 Dec;14(12):1623-1631. doi: 10.1016/j.jalz.2018.06.3053. Epub 2018 Jul 26.

PMID:
30055132
13.

Revolution of Alzheimer Precision Neurology. Passageway of Systems Biology and Neurophysiology.

Hampel H, Toschi N, Babiloni C, Baldacci F, Black KL, Bokde ALW, Bun RS, Cacciola F, Cavedo E, Chiesa PA, Colliot O, Coman CM, Dubois B, Duggento A, Durrleman S, Ferretti MT, George N, Genthon R, Habert MO, Herholz K, Koronyo Y, Koronyo-Hamaoui M, Lamari F, Langevin T, Lehéricy S, Lorenceau J, Neri C, Nisticò R, Nyasse-Messene F, Ritchie C, Rossi S, Santarnecchi E, Sporns O, Verdooner SR, Vergallo A, Villain N, Younesi E, Garaci F, Lista S; Alzheimer Precision Medicine Initiative (APMI).

J Alzheimers Dis. 2018;64(s1):S47-S105. doi: 10.3233/JAD-179932. Review.

14.

α-Synuclein Heterocomplexes with β-Amyloid Are Increased in Red Blood Cells of Parkinson's Disease Patients and Correlate with Disease Severity.

Daniele S, Frosini D, Pietrobono D, Petrozzi L, Lo Gerfo A, Baldacci F, Fusi J, Giacomelli C, Siciliano G, Trincavelli ML, Franzoni F, Ceravolo R, Martini C, Bonuccelli U.

Front Mol Neurosci. 2018 Feb 22;11:53. doi: 10.3389/fnmol.2018.00053. eCollection 2018.

15.

Blood-Based Biomarker Screening with Agnostic Biological Definitions for an Accurate Diagnosis Within the Dimensional Spectrum of Neurodegenerative Diseases.

Baldacci F, Lista S, O'Bryant SE, Ceravolo R, Toschi N, Hampel H; Alzheimer Precision Medicine Initiative (APMI).

Methods Mol Biol. 2018;1750:139-155. doi: 10.1007/978-1-4939-7704-8_9.

PMID:
29512070
16.

Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.

Dubois B, Epelbaum S, Nyasse F, Bakardjian H, Gagliardi G, Uspenskaya O, Houot M, Lista S, Cacciamani F, Potier MC, Bertrand A, Lamari F, Benali H, Mangin JF, Colliot O, Genthon R, Habert MO, Hampel H; INSIGHT-preAD study group.

Lancet Neurol. 2018 Apr;17(4):335-346. doi: 10.1016/S1474-4422(18)30029-2. Epub 2018 Feb 27. Erratum in: Lancet Neurol. 2018 Apr 25;:.

PMID:
29500152
17.

Precision pharmacology for Alzheimer's disease.

Hampel H, Vergallo A, Aguilar LF, Benda N, Broich K, Cuello AC, Cummings J, Dubois B, Federoff HJ, Fiandaca M, Genthon R, Haberkamp M, Karran E, Mapstone M, Perry G, Schneider LS, Welikovitch LA, Woodcock J, Baldacci F, Lista S; Alzheimer Precision Medicine Initiative (APMI).

Pharmacol Res. 2018 Apr;130:331-365. doi: 10.1016/j.phrs.2018.02.014. Epub 2018 Feb 16. Review.

PMID:
29458203
18.

α-Synuclein Aggregated with Tau and β-Amyloid in Human Platelets from Healthy Subjects: Correlation with Physical Exercise.

Daniele S, Pietrobono D, Fusi J, Lo Gerfo A, Cerri E, Chico L, Iofrida C, Petrozzi L, Baldacci F, Giacomelli C, Galetta F, Siciliano G, Bonuccelli U, Trincavelli ML, Franzoni F, Martini C.

Front Aging Neurosci. 2018 Jan 30;10:17. doi: 10.3389/fnagi.2018.00017. eCollection 2018.

19.

Alzheimer's disease biomarker-guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: Aβ1-42, total-tau, phosphorylated-tau, NFL, neurogranin, and YKL-40.

Hampel H, Toschi N, Baldacci F, Zetterberg H, Blennow K, Kilimann I, Teipel SJ, Cavedo E, Melo Dos Santos A, Epelbaum S, Lamari F, Genthon R, Dubois B, Floris R, Garaci F, Lista S; Alzheimer Precision Medicine Initiative (APMI).

Alzheimers Dement. 2018 Apr;14(4):492-501. doi: 10.1016/j.jalz.2017.11.015. Epub 2018 Jan 9.

PMID:
29328927
20.

Oxidative Stress Assessment in Alzheimer's Disease: A Clinic Setting Study.

Vergallo A, Giampietri L, Baldacci F, Volpi L, Chico L, Pagni C, Giorgi FS, Ceravolo R, Tognoni G, Siciliano G, Bonuccelli U.

Am J Alzheimers Dis Other Demen. 2018 Feb;33(1):35-41. doi: 10.1177/1533317517728352. Epub 2017 Sep 21.

PMID:
28931301

Supplemental Content

Loading ...
Support Center